INTRODUCTION
Lysosomal acid lipase (LAL) is a key enzyme for intracellular lipid metabolism, which regulates the intra-lysosomal hydrolysis of cholesterol esters (CE) and triglycerides (TG), producing free cholesterol and fatty acids [1] . The LAL activity reduction causes intra-lysosomal accumulation of CE and lowers free cholesterol in cytosol [2] . This reduction increases transcription factor sterol regulatory element binding protein activity, which promotes lipogenesis and synthesis of cholesterol and of very lowdensity lipoproteins. In addition, there is a reduction in liver X receptors expression resulting in impaired cholesterol efflux and high-density lipoprotein (HDL) production [3] . Moreover, low-density lipoprotein (LDL) receptor synthesis and the receptor-mediated LDL uptake are amplified.
In patients with both heterozygous or homozygous deletion of lipase A (LIPA) gene, a lipid phenotype similar to that observed in patients with familial hypercholesterolemia (FH) has been described [4, 5] . Therefore, in presence of hypercholesterolemia with type IIa phenotype, it is very important, but not always easy, to make a differential diagnosis with heterozygous FH (Table 1) . A family history for early cardiovascular disease and/or hypercholesterolemia supports a diagnosis of heterozygous FH. On the contrary, in the absence of diagnostic criteria for FH, a LAL defect could be suspected, especially in patients with hypercholesterolemia associated with low levels of HDL cholesterol. The Dutch Lipid Clinic Network score [6, 7] or the Simon Broome criteria [8] for FH may be two useful tools for a differential diagnosis.
GENETICS OF LAL DEFICIENCY
LAL deficiency (LAL-D) is a rare autosomal recessive genetic disease due to a mutation in the LIPA gene, characterized by the presence of CE and TG in numerous tissues. The most common mutation is the E8SJM variant, which has an estimated frequency of 0.00025 in the general population (i.e., 1 carrier per 200 individuals in Western countries). The LAL-D is a heterogeneous disorder that may present with two different phenotypes based on residual LAL activity levels (Figures 1): Wolman's disease and cholesterol ester storage disease (CESD) [1, 4] . Wolman's disease starts prematurely during the 6th or 7th mo of life and quickly leads to death, with only a small proportion of patients surviving beyond the first year of age. Infants with LAL-D show delayed growth, associated with signs of malabsorption, hepatosplenomegaly, severe hepatic dysfunction, rapidly progressive anemia, and multi-organ failure; the adrenal calcifications are the pathognomonic sign of Wolman's disease. In these patients, LAL activity is almost null [1] . CESD is the late onset phenotype, being manifested during childhood, adolescence, or in adulthood, with onset age ranging from 5 to 44 years or more. It presents with hepatic steatosis, high levels of aminotransferase, hepatomegaly, and dyslipidemia. As the clinical manifestations of CESD are not very characteristic, the diagnosis is often occasional. The clinical phenotype and disease severity are very variable and depend on the residual enzymatic activity, which is usually less than 12%. Therefore, the coexistence of hepatic steatosis and hypercholesterolemia, in particular in nonobese subjects, should lead to the differential diagnosis between LAL-D and other metabolic causes of non-alcoholic fatty liver disease (NAFLD), such as metabolic syndrome, type II diabetes, hypertriglyceridemia, and central obesity [9] .
LIVER ALTERATIONS IN LAL-D
LAL-D leads to CE and TG accumulation in hepatocytes and liver-resident macrophages (Kupffer cells) with subsequent progression to fibrosis (Figures 2). The high prevalence of severe fibrosis in LAL-D and its rapid progression to cirrhosis suggest that lysosomal CE and TG accumulation is a potent driver of liver fibrosis [9] [10] [11] . A recent study showed increased transaminases in hepatocyte-specific LAL-deficient mice (Liv-Lipa -/-) as well as upregulation of hepatic cytokines and chemokines, known to drive inflammation and leading to Kupffer cell activation and liver damage [12] . In addition, lysosomal CE accumulation induces Kupffer cell activation, causing inflammation and liver damage in high fat/high cholesterol fed Liv-Lipa-/-mice. These findings indicated that hepatocytes' LAL plays a critical role for liver homeostasis and function.
A recent study reported data on allograft recurrence, liver failure, and other clinical outcomes in 18 liver transplantation (LT) LAL-D patients. LT was necessary for treatment of LAL-D-associated liver failure but, interestingly, did not correct LAL activity, which remained deficient post-LT [13] . Therefore, LT does not correct deficient LAL enzyme in bone marrow derived histiocytes; moreover, LT does not even prevent multi-organ disease progression or liver disease recurrence, as observed in liver biopsies within the first year following LT.
In addition, Burton et al [14] have shown how, in patients with genetic LAL deficiency, 20 wk treatment with enzyme replacement therapy (Sebelipase-alpha) is able to reduce hepatic fat evaluated by magnetic resonance. In addition, treated patients showed serum liver enzymes and serum lipids improvement. The term NAFLD indicates a set of diseases associated with the presence of excessive accumulation of hepatic fat in the absence of chronic viral infection and alcohol abuse. NAFLD is the most common hepatic disease. It is estimated that the prevalence in the general population is about 20%-30%, reaching up to 70%-90% in the obese or diabetic population [15] . NAFLD, in the initial phases, presents as simple steatosis, whose main histological finding is the presence of predominantly macrocytic steatosis in at least 5% of hepatocytes. In some cases, simple steatosis evolves into non-alcoholic steatohepatitis (NASH), in which the histological picture includes steatosis, ballooning, and inflammation with a progressive increase in fibrosis. In the past, NAFLD was considered a benign condition; however, recent evidence suggests a less favorable prognosis, due to the possible evolution in cirrhosis, hepatocellular carcinoma, and hepatic failure [16] . Today, NAFLD is considered the main cause of cryptogenic cirrhosis, the prevalence of which is increasing in recent years, especially in patients with history of obesity and type II diabetes. NAFLD is the second indication for liver transplantation in the US and is expected to exceed hepatitis C virus (HCV) in the next few years, becoming the first cause for liver transplant [17] . Numerous pathogenic factors contribute to the accumulation of lipids in the hepatocytes and, in a proportion of patients, the development of fibrotic processes [18] . Among them, insulin resistance, oxidative stress, and low-grade chronic inflammation supported by the production of cytokines deriving from visceral fat. However, the pathogenic mechanisms underlying the progression of simple steatosis to NASH and cirrhosis are not yet fully clarified nor are tools available to predict the evolution of NAFLD.
LAL ACTIVITY REDUCTION AND NAFLD
Prospective studies suggest that the first cause of death in patients diagnosed with NAFLD is cardiovascular disease [19, 20] . Atherosclerosis is very common in these subjects, and many of them, especially before the onset of liver complications, develop coronary heart disease [21] . The relationship between NAFLD and cardiovascular risk has long been investigated [15, [22] [23] [24] . According to the "multiple parallel hits hypothesis", many insults, including insulin resistance, the presence of gene variants, oxidative stress, and alteration of the intestinal microbiota, act simultaneously on the liver causing lipid infiltration and inflammation [18] . It remains to be clarified whether it is the metabolic syndrome that promotes steatosis through insulin resistance, or whether it is NAFLD that induces hyperinsulinemia through a defective mechanism of insulin degradation. The current opinion suggests a bidirectional link between NAFLD and the metabolic syndrome [25] . Few studies have so far assessed the activity of LAL in patients with NAFLD, and the possible role of LAL as one of the multiple hits in NAFLD pathogenesis is under debate [26] . Our group [27] has recently demonstrated reduced LAL activity in patients with NAFLD. LAL activity was significantly reduced in 240 patients with NAFLD compared to 100 heathy subjects (HS) [0.78 (0.61-1.01) nmol/spot per hour vs 1.15 (0.94-1.72) nmol/spot per hour, P < 0.001]. An even more marked reduction was observed in patients with histologically diagnosed NASH [0.67 (0.51-0.77) nmol/spot per hour, P < 0.001 vs HS; P < 0.001, between the groups]. In addition, patients with NAFLD who exhibited enzymatic activity below the median had higher serum total cholesterol (P < 0.05) and LDL cholesterol (P < 0.05) and higher levels of transaminases and gamma-glutamyltransferase (alanine aminotransferase, P < 0.001; aspartate aminotransferase, P < 0.01; gamma-glutamyltransferase, P < 0.01).
Therefore, based on our findings, it was possible to hypothesize that the reduction of LAL activity, as well as a predisposing factor for the development of NAFLD, could be considered as a further pathophysiological mechanism for progression to NASH and eventually to cryptogenic cirrhosis. Moreover, based on the above observations [28] , we could also hypothesize that LAL activity can constitute a possible tool for the identification of the subjects with more advanced forms of NAFLD and possibly for the monitoring of the response to therapy.
Shortly thereafter [29] , a significant reduction in LAL activity in a series of pediatric cases was also observed. In this study, children with significant fibrosis (stage 2-3, n = 64) had a significantly lower LAL activity compared to those with mild fibrosis (stage 0-1, n = 104), suggesting a potential role of reduced LAL activity in the pathogenesis of NAFLD-induced fibrosis.
In a further study [30] , we found that NAFLD patients disclosed a relatively high prevalence of spleen enlargement and splenomegaly, which were significantly associated with a reduced LAL activity, suggesting that LAL may contribute to spleen enlargement in this setting. Although the degree of LAL activity reduction was less pronounced compared to genetic forms of LAL deficiency, which develop severe fat accumulation in the spleen, a similar mechanism may be hypothesized.
More recently, Tovoli et al [31] performed a study of LAL activity in 81 patients with a diagnosis of NAFLD and 78 matched controls with HCV-related liver disease. LAL activity was significantly reduced in NAFLD compared to that in HCV patients, suggesting that NAFLD is characterized by a specific deficit in LAL activity.
Finally, in a study by Gomaraschi M et al [32] , 164 patients with biopsy-proven NAFLD were compared with 60 dyslipidemic patients with similar prevalence of metabolic syndrome and 30 controls. LAL activity on dried blood spot (DBS) was reduced in NAFLD patients compared to controls and those with dyslipidemia.
Therefore, we may conclude that the reduction of LAL activity, even in the absence of genetic diseases, seemed to be associated with the development of progressive hepatic steatosis (Table 2) .
LAL-D AND LIVER CIRRHOSIS
Based on follow-up studies, 25% of patients affected by NASH may develop cirrhosis and eventually hepatocellular carcinoma. In fact, current knowledge strongly indicates that cryptogenic cirrhosis is, in truth, the evolution of NASH. However, the mechanisms underlying disease progression remain poorly understood. Following evidence from NAFLD, we hypothesized that epigenetic and/or environmental [30] 315 NAFLD patients; with US spleen dimensions evaluation Median LAL activity was: 0.9 (0.7-1.2) in patients with normal spleen; 0.7 (0.6-0.9) in patients with splenomegaly
Spleen enlargement and splenomegaly were significantly associated with a reduced LAL activity 2017 Tovoli et al [31] 81 NAFLD patients; (53.1% with cirrhosis) 22 patients aged 1-75 years who underwent liver biopsy; 13 at high risk for LAL-D (microvesicular steatosis or with cryptogenic cirrhosis); 9 at low risk for LAL-D; (microvesicular steatosis in metabolic/NAFLD patients)
Mean LAL activity was 0.74 ± 0.28 and was similar in both risk groups; 37.5% had LAL < 0.5 LAL < 0.5 was associated with markers of liver disease severity 2017 Tovoli et al [31] 81 NAFLD patients; (53.1% with cirrhosis)
Median LAL activity was: 0.53 (0.29-0.69) in cirrhotic NAFLD patients; 0.67 (0.50-0.89) in cirrhotic HCV patients LAL activity is significantly reduced in NAFLD-related cirrhosis compared to HCVcirrhosis 78 HCV patients; (59.0% with cirrhosis) 2017 Angelico et al [33] 133 CC patients; 141 KAC patients modulation of LAL activity could be also an unrecognized contributing factor in the progression to cryptogenic cirrhosis.
To evaluate a possible role of LAL in cryptogenic cirrhosis, we carried out a cohort study including 274 patients with liver cirrhosis of different etiology from 19 centers in Italy [33] . Median LAL activity value was 0.58 nmol/spot per hour, 0.49 and 0.65 in the cryptogenic cirrhosis and alcoholic/viral cirrhosis groups, respectively (P < 0.002). Approximately 30% of patients with cryptogenic cirrhosis showed a severe reduction Shteyer et al [35] performed a study on medical records of 22 patients with microvescicular steatosis and cryptogenic cirrhosis and 9 with NAFLD diagnosed with liver biopsies. LAL activity inversely predicted liver disease severity, and LAL level of 0.5 was the most sensitive for detecting both histologic and non-invasive markers for disease severity ( Table 2) .
WHOM TO MEASURE LAL ACTIVITY?
LAL-D should be suspected in non-obese subjects with NAFLD and/or cryptogenic cirrhosis, unexplained persistently elevated levels of transaminases, and/or high levels of LDL cholesterol and low HDL cholesterol.
In these subjects, it would be appropriate to measure LAL activity using the DBS test, which is a simple and inexpensive test that determines the enzymatic activity on the blood spot, subtracting from the activity of the total lipase obtained after addition of a specific LAL inhibitor (Lalistat 2). All patients with a marked reduction in LAL activity (≤ 0.4 nmol/spot per hour) should be investigated for the presence of LIPA gene mutations. Patients homozygous for LAL deficiency have a residual activity equal to or close to 0. The lower limit of the range of normality in the validation tests of the method was 0.8 nmol/spot per hour.
CONCLUSION
A reduced LAL activity may contribute to liver damage in patients with NAFLD, but several issues need to be addressed to better understand the role of LAL in liver diseases. First, there are no reliable in vivo data on LAL activity modulation. In particular, epigenetic and environmental factors that are able to regulate its activity in subjects without homozygous mutations of the LIPA gene have not yet been identified. For example, it is not known whether an intervention on modifiable cardiometabolic risk factors, typically associated with NAFLD, such as metabolic syndrome, diabetes, overweight, or oxidative stress, may affect the modulation of LAL activity in a favorable manner. Moreover, it is still unclear whether low LAL activity may predict liver disease progression and or cardio-metabolic events.
Besides, the specific contribution of circulating cells to the total activity of LAL on the DBS test is still unclear. In a study of a random sample of 300 subjects, LAL activity, measured with 4-methyl-umbelliferyl oleate as the substrate, was present in high concentration in lymphocytes and monocytes but not in polymorphonuclear leukocytes [36] . Recently, in a study performed in 172 HS aged ≥ 18 years, LAL activity in white blood cells was significantly higher than in platelets (458.9 ± 133.6 nmol/mg per hour vs 235.0 ± 88.3 nmol/mg per hour, P < 0.001). However, LAL activity in DBS correlated more strongly with that in platelets, suggesting that platelet count is recommended before interpreting LAL activity in DBS [37] . In addition, it remains to be clarified whether any improvement in the enzymatic activity could result in a reduction of hepatic fat in patients with NAFLD. In light of the results of a recent clinical trial with Sebelipase-alfa, it can be hypothesized that the modulation of LAL activity may become a possible new therapeutic target in the future, even in conditions of less severe reductions of LAL activity [14] . This could mainly concern patients with more advanced forms of NAFLD, such as those with NASH or cryptogenic cirrhosis for which, at present, there are no effective therapies [33, 38] . In conclusion, the measurement of LAL activity in patients with NAFLD may be a new non-invasive marker of liver disease severity.
